Low-Dose Hydrocortisone/Antifungal Development Urged At FDA Committee
Executive Summary
A half-percent hydrocortisone combined with an antifungal would satisfy an unfulfilled primary-care need for a combination drug to treat skin problems that may or may not be fungal, FDA Dermatologic & Ophthalmologic Drugs Advisory Committee member William Rosenburg, MD, recommended June 29.
You may also be interested in...
FDA Limits Schering Lotrisone Indication, Approves Lotion Formulation
Schering-Plough Lotrisone cream is no longer indicated to treat symptoms of tinea caused by Microsporum canis, following a labeling change.
FDA Limits Schering Lotrisone Indication, Approves Lotion Formulation
Schering-Plough Lotrisone cream is no longer indicated to treat symptoms of tinea caused by Microsporum canis, following a labeling change.
Schering Lotrisone Warnings Should Be Milder, FDA Committee Says
Schering-Plough Lotrisone labeling should sufficiently warn against use of the drug in children under 12 but should not be so severe that physicians who use it off label for valid reasons are intimidated, FDA's Dermatologics & Ophthalmics Advisory Committee said.